Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

BAM_lab_eyetracking_03

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

2024-03-05

2025-06-01

2025-07-30

Recruiting

80

Inclusion Criteria: * Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent. * Normal or corrected-normal version Exclusion Criteria: * History of neuropsychiatric diseases. * History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness. * History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction. * History of renal diseases, including renal stones or renal failure. * History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus * Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food. * Infections such as COVID-19 or influenza, or unexplained fever. * Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg). * History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Randomized placebo-controlled double-blind between-subject design', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}

2024-04-11